WCN26-4775 SUCCESSFUL TREATMENT OF A PATIENT WITH C3 GLOMERULOPATHY (C3G) WITH IPTACOPAN: 10 MONTHS EXPERIENCE

Read full text Summarise with VIRAT
Authors: Ioannis Griveas
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

C3G is a complex, ultra rare, progressive primary glomerulonephritis with an estimated annual incidence of 1-2 cases per million. The pathogenesis of C3G centers on the overactivation of the alternative complement pathway (AP) as a result of nephritic factors or genetic mutations. Until recently there was no approved targeted therapy for C3G and the suggested management options (KDIGO 2021, but not based on controlled studies) include supportive care including blood pressure management-antiproteinuric therapy with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, immunosuppression and life-style modifications.

Fields of Study & Subjects

Complement system in diseases Renal Diseases and Glomerulopathies Vasculitis and related conditions

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104793–104793
Publication date
25 March 2026
Language
EN